A prospective open-label study of aripiprazole in the management of patients with schizophrenia in general psychiatric practices.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2013
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Otsuka Pharmaceutical Development & Commercialization
- 16 Feb 2010 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
- 26 Dec 2007 Status changed from in progress to completed.
- 22 Oct 2006 New trial record.